Now let me check the "24/7 Wall St" and "Trefis" articles for bull/bear framing, and gather info on the melanoma interim timing update and Q2 revenue guide vs consensus gap.I now have a comprehensive picture. Let me write the earnings preview.# Moderna (MRNA) Q2 2026 Earnings Preview Report Date: Friday, July 31, 2026, before market open | Call: 8:00 a.m. ET
Moderna's stock has been on a wild ride in 2026. Shares started the year near $31, rallied hard through late June and early July on a string of pipeline and regulatory wins — peaking above $80 in early July — before pulling back roughly 25-30% into earnings, closing around $58 on July 30. That leaves the stock up more than 80% year-to-date even after the recent drawdown, making this print an important test of whether the rally is justified by fundamentals or has gotten ahead of itself.
Sentiment is decidedly split. Consensus analyst ratings remain largely stuck at Hold, with price targets spanning an unusually wide range (roughly $18-$25 on the low end to as high as $77 on the bullish end). JPMorgan reiterated a Sell rating and named Moderna one of its top short ideas heading into Q3, contributing to a sharp ~11-12% single-day drop on July 10. Other bearish flags include a large Susquehanna position cut in Q1 and a pre-planned insider sale by President Stephen Hoge in mid-July. On the other side, options positioning looks call-skewed ahead of the print, and prediction markets have been pricing a high probability of another earnings beat.
Moderna has beaten revenue and EPS estimates in each of the last several quarters, including a large Q1 2026 beat ($389M actual vs. ~$236M consensus, +264% YoY). For Q2 2026, Wall Street estimates have varied widely by source, but the Zacks consensus calls for revenue of roughly $126.7 million and an EPS loss of about $1.97, while other trackers show estimates closer to $103 million in revenue and a loss near $2.00. Management's own Q1 call guidance pointed to Q2 revenue of just $50-100 million (evenly split U.S./international), which would put first-half 2026 revenue around $440-490 million — noticeably below some sell-side estimates, setting up a key swing factor for the quarter.
Key financial framework items to watch: - Full-year revenue growth target: Management has reiterated guidance for up to 10% revenue growth in 2026 (roughly 50/50 U.S./international split), and investors will want confirmation this is still on track, especially given normalizing COVID vaccination demand and a slow mRESVIA (RSV) launch. - Cost discipline: 2026 guidance calls for R&D of ~$3.0 billion, SG&A of ~$1.0 billion, and adjusted cash costs of ~$4.2 billion (a continuation of the ~26% YoY cash cost reduction seen in Q1). Investors will look for confirmation the company remains on pace. - Cash burn and the Arbutus settlement: Moderna ended Q1 with $7.5 billion in cash and investments and guided to a $4.5-5.0 billion year-end cash position. Critically, the $950 million lump-sum payment tied to the Arbutus/Genevant litigation settlement is due in Q3 2026 — this quarter's cash flow commentary and any update on the pending Section 1498 government-contractor-immunity appeal (which could trigger up to an additional $1.3 billion liability if Moderna loses, expected to resolve in late 2027/2028) will be closely watched.
The single largest near-term catalyst sits just days after earnings. Moderna's seasonal flu vaccine, mRNA-1010 (branded mFlusiva), has a PDUFA date of August 5, 2026, and received a unanimous 9-0 FDA advisory committee vote in June affirming its benefit-risk profile in adults 50 and older. Approval would make it Moderna's fifth commercial product and begin rebuilding its respiratory franchise ahead of the 2026-2027 flu season. Notably, management has not guided for any 2026 revenue contribution from flu (or from the mCOMBRIAX flu+COVID combo, which is still awaiting FDA guidance on U.S. refiling after receiving EU approval), partly reflecting lessons learned from mRESVIA's slower-than-expected RSV launch amid competition from GSK and Pfizer. Bears note Moderna also missed the main 2026-2027 U.S. flu contracting window, meaning even an approval may not translate to meaningful near-term sales.
Beyond respiratory vaccines, the biggest value driver for the stock is intismeran autogene (mRNA-4157), Moderna's individualized cancer therapy partnered with Merck: - A Phase 3 adjuvant melanoma interim analysis is expected sometime in 2026 (sell-side estimates have pointed to an October/November window), building on five-year Phase 2b data presented at ASCO showing intismeran plus KEYTRUDA reduced the risk of recurrence or death by 49% versus KEYTRUDA alone. UBS has framed this as a binary-type catalyst that could move the stock 25-50% on success. - Moderna also just initiated a new Phase 3 monotherapy/combination study in high-risk Stage 1 non-small cell lung cancer, expanding intismeran into earlier-stage disease where standard of care today is largely surgery and watchful waiting. - Additional oncology readouts (mRNA-4359 in Phase 2, RCC and bladder cancer interim data) are pending later in 2026.
Bull case: Continuation of the beat streak (five straight quarters), reiteration of the up-to-10% revenue growth target, cost discipline tracking toward the ~$4.2B cash-cost target, and constructive commentary ahead of the August 5 flu decision and the pending melanoma interim analysis — all of which could support the stock's 2026 rally continuing.
Bear case: Revenue guidance for Q2 already implied a soft quarter ($50-100M per management's own framework, well below some outside estimates), COVID demand normalization continues to weigh on the base business, mRESVIA's launch has been underwhelming, the $950M Arbutus payment is a near-term cash drag, and skeptics (JPMorgan, some Seeking Alpha authors) argue the stock's 2026 surge has run ahead of near-term commercial reality, particularly given Moderna missed the main 2026-2027 flu contracting cycle even if mRNA-1010 is approved.
This print is less about the absolute revenue/EPS numbers — which are still small in dollar terms relative to Moderna's ~$23-24B market cap — and more about management's tone on (1) full-year growth and cost guidance, (2) cash trajectory ahead of the Q3 Arbutus payment, and (3) any incremental color on the flu PDUFA (just five days later) and the eagerly awaited melanoma Phase 3 interim analysis. Given the stock's sharp round-trip in 2026, volatility around the report and the following week is likely to be elevated regardless of the print's specifics.